Spark Therapeutics, Inc. (ONCE): Jeffrey D Marrazzo , Chief Executive Officer of Spark Therapeutics, Inc. sold 25,000 shares on May 19, 2016. The Insider selling transaction was reported by the company on May 23, 2016 to the Securities and Exchange Commission. The shares were sold at $46.36 per share for a total value of $1,150,258.50 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 23, 2016, Barge Joseph La (officer ) sold 10,000 shares at $48.44 per share price.On Apr 22, 2016, Coelho Rogerio Vivaldi (Chief Commercial Officer) sold 7,000 shares at $40.02 per share price.Also, On Jan 4, 2016, Hospital Of Philade Children’s (10% owner) sold 131,505 shares at $44.18 per share price.On Dec 4, 2015, Katherine A High (director officer ) sold 10,000 shares at $55.31 per share price.
Spark Therapeutics Inc: On Friday, May 20, 2016 heightened volatility was witnessed in Spark Therapeutics Inc which led to swings in the share price. The shares opened for trading at $46.92 and hit $51.33 on the upside , eventually ending the session at $50.84, with a gain of 7.78% or 3.67 points. The heightened volatility saw the trading volume jump to 9,24,317 shares. The 52-week high of the share price is $76.24 and the company has a market cap of $1,392,914 M . The 52-week low of the share price is at $21.2.
Company has been under the radar of several Street Analysts.Spark Therapeutics Inc is Initiated by Wedbush to Underperform and the brokerage firm has set the Price Target at $21. The Rating was issued on Mar 31, 2016.Spark Therapeutics Inc is Initiated by Goldman to Neutral. The Rating was issued on Mar 30, 2016.Spark Therapeutics Inc is Initiated by Sun Trust Rbsn Humphrey to Buy and the brokerage firm has set the Price Target at $64. The Rating was issued on Mar 22, 2016.Spark Therapeutics Inc is Reiterated by Chardan Capital Markets to Neutral while Lowering the Price Target of the company shares to $ 35 from a previous price target of $45 . The Rating was issued on Mar 18, 2016.
Spark Therapeutics Inc. (Spark) is engaged in developing products in the field of gene therapy. Spark’s product candidate SPK-RPE65 which is in Phase III clinical trial stage targets a group of rare blinding conditions known as inherited retinal dystrophies (IRDs) caused by non-sex linked or autosomal recessive mutations in the RPE65 gene. Spark is also developing various follow-on product candidates targeting other IRDs including SPK-CHM for the treatment of choroideremia (CHM). SPK-CHM is in Phase I/II dose-escalating clinical trial stage. The Company’s product development portfolio includes product candidates targeting expression of genes in the liver with a focus on hematologic disorders. The Company is also engaged in the development and commercialization of product candidates in its SPK-FIX program for the treatment of hemophilia B. Spark also has preclinical programs in development for the treatment of hemophilia A and neurodegenerative diseases.